Revolutionizing Targeted
Therapies
Integrating Immune-Omics & Intelligent Discovery in a way that we call Immune Orchestration
We Are
Pioneers
Pioneera Biosciences is founded by a team of award-winning scientists and engineers developing best-in-class Immunotherapies and CAR-X “living drugs” powered by AI-driven design and non-viral delivery.
We stand out through our resistance-proof technology, patient-focused values, and commitment to advancing safer, more effective cell and gene therapies
1
Intelligent Construct Discovery
+300 CARs and ScFvs generated and tested
Our core AI platform, Discovery 4.0™, is trained in a federated manner to prevent antigen escape while designing best-in-class CARs, scFvs, and heavy-chain domains. Our validated algorithm maps dynamic changes in antigen surfaces, giving us the flexibility to generate superior candidates across multiple therapeutic classes—including Cell and Gene Therapies (CAR-Ts, CAR-NKs), monoclonal antibodies, and Radiopharmaceuticals.
2
Oncology
Allogenic CAR-X Modalities
By focusing initially on hematological malignancies, we are laying the foundation to expand into advanced solid tumors. Our CAR-T program targets Multiple Myeloma, and our mRNA-CAR-NK therapy is designed for B-cell malignancies, supported by an ongoing research program developing novel Pioneera CAR-expressing immune cell subtypes. This approach strengthens our ability to fully harness and amplify the true power of the immune system.
3
Autoimmune Diseases
Validated Proof of Concepts
While our NK-focused mRNA-LNP transduction platform holds strong potential for in-vivo administration, we have also received positive clinical interest from physicians to advance our B-cell–targeted CAR-NK program into autoimmune indications. In parallel, we are conducting active research on a CAR-T modality for undisclosed autoimmune disease targets, further expanding our commitment to next-generation immune-modulating therapies.
While we continue to advance best-in-class immunotherapies and CAR designs through intelligent, pan-omics–integrated, and personalized translational strategies, ensuring broad patient access to these life-saving treatments remains one of our highest priorities and a central pillar of our mission.
Dr. Alireza Daneshvar, PharmD, MPH
CEO and Co-Founder of Pioneera Biosciences
Our Team
Rakhshan Mashayekhi,
PhamrD
Chief Scientific Officer
Alireza Daneshvar,
PharmD, MPH
Chief Executive Officer
Mohammad H. Sharifnia
PharmD, PhD
Chief Innovation & AI Officer
Our Advisory Board
Our Advisory Board brings together world-class scientists, clinicians, and industry leaders who guide Pioneera’s strategic, scientific, and translational direction.
Prof. Chris Mason
Professor of Cell and Gene Therapy - UCL
Prof. Alireza Haghighi
Executive Director of iCGD - Harvard Medical School
Elena Bonfiglioli
Global Manager Pharma and Life Sciences - Microsoft
Dr. Behzad Mahdavi
Ex-Lonza, Ginkgo Bioworks
Strategic Growth Leader
Dr. Mustafa Munye
VP of Operations Complement Therapuetics